Is AbbVie the Next AstraZeneca?

Abbott Labs (NYSE: ABT  ) will be spinning off its branded pharmaceuticals department into a new company, AbbVie, an event that will take place at the beginning of 2013. But while Abbott shareholders aren't due to get their special dividend of one share of AbbVie for each share of Abbott that they own until Jan. 1, shares of the new company are already trading on a when-issued basis. Late last week, Motley Fool health care bureau chief Brenton Flynn discussed how this allows us to see the market's valuation of the stock a bit early and why its current price shows that there may be some patent cliff fears.

To help investors better understand the upcoming spinoff, the Fool has created a brand new premium report outlining both Abbott Labs and AbbVie. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this 2-for-1 report by clicking here now


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2163704, ~/Articles/ArticleHandler.aspx, 7/23/2014 11:24:37 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement